Druckversion

Archiv: Mitteilungen

22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


22.04.2014

Biogen prices hemophilia drug on par with older therapies Biogen prices hemophilia drug on par with older therapies

Exclusive: Biogen prices hemophilia drug on par with older therapies | Business | Reutersca.reuters.com(Reuters) - Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and...[mehr]


Treffer 1 bis 10 von 1136
<< Erste < Vorherige 1-10 11-20 21-30 31-40 41-50 51-60 61-70 Nächste > Letzte >>